Shares of IMRIS off to fast start in 2015

Byron Capital Healthcare and Biotech analyst Douglas Loe says his aggressively postitive view that IMRIS's order flow can ramp up is based on the value proposition the company's products offer to hospital clients, which he believes are more than compelling.

Shares of IMRIS (TSX:IM, Nasdaq:IMRS) are up 18.2% today, a result shareholders must be growing used to in 2015. Since January 9th, when its shares closed at $0.72, IMRIS has nearly doubled, currently trading at $1.30. Those looking for a reason for the recent surge can probably point to the company’s press release of January […]

Miraculins President and CEO Christopher Moreau talks to Cantech Letter

Miraculins President and CEO Christopher Moreau

We are constantly and correctly reminded that early screening for a variety of diseases and conditions can drastically increase our chances of beating them. Yet for a myriad of problems, many of us end up simply avoiding the doctor’s office. We are too tired. We hate needles. And we’re probably fine, right? What if the […]

Who is Lying to Parents About Vaccines and Why?

Dr. Jonas Salk, who discovered and developed the first successful inactivated polio vaccine.

In light of recent outbreaks of measles and other vaccine preventable illnesses, and the refusal of anti-vaccination advocates to acknowledge the problem, I thought it was past time for this post. Dear parents, You are being lied to. The people who claim to be acting in the best interests of your children are putting their […]

Meet the new billion dollar Tekmira


In a transformational deal announced earlier this week, Tekmira Pharmaceuticals (TSX:TKM, Nasdaq:TKMR) plans to merge with private OnCore Biopharma, redefining itself as a company focused predominantly on hepatitis B (HBV) therapeutics and less on RNA interference (RNAi). The new Tekmira will have a pipeline of 8 drugs targeting HBV, as they try to follow the […]

Is Gordie Howe’s Trip to Mexico An Example of “Stem Cell Tourism”?


Hockey legend Gordie Howe emerged from a round of stem cell treatment in Mexico just before Christmas, the results of which his family described as “truly miraculous”. This after a long period during which Howe had been “had been rapidly declining and was essentially bedridden with little ability to communicate or to eat on his […]

Bedrocan Cannabis is my top pick for 2015, says M Partners’ Pearlstein


Analysts at M Partners unveiled their top picks for 2015 today and Daniel Pearlstein says Bedrocan Cannabis (TSXV:BED) is his. Bedrocan Cannabis, which was formed in 2012, is the Canadian licensee of Bedrocan BV, which has been a Dutch government-contracted licensed producer for the past 13 years. Pearlstein says Bedrocan’s agreement with its Dutch partner […]

IMRIS soars after insider buying


Shares of IMRIS (TSX:IM) are up sharply today after a Christmas present from an insider. On Christmas Eve day the company announced that existing investor Centara Corp. had purchased 2.37-million units of a private placement priced at $0.284 that included one share and a quarter warrant. The warrant entitles the buyer to acquire one common […]

TS03 Gives Investors an Early Christmas Present

TS03's low-temperature 125 litre STERIZONE® sterilizer is designed for terminal sterilization of heat and moisture sensitive medical devices.

It may have taken four years, but TS03 has finally received FDA 510(k) clearance for its Sterizone VP4 Sterilizer. The 510(k) clearance allows TS03 to sell their low-temperature sterilizer in the U.S., and should also galvanize the company’s ongoing partnering discussions. However, TS03 does not plan to delay the commercial launch while negotiating with prospective […]

2014 Cantech Letter TSX Life Sciences Stock of the Year: The Finalists


It was a wild year for Life Sciences stocks on the TSX, with exciting new entrants and several stocks that raced. Headlines in 2014 were dominated by Valeant’s ultimately unsuccessful bid to acquire Botox-maker Allergan, but were spiked with the stories of Cipher Pharmaceuticals, which soared on the promise of a strong lead drug, the […]